French data reveals which arthritis drug better shields patients from heart attacks and strokes
NCT ID NCT07459335
Summary
This study looked back at French health records to compare two drugs—tocilizumab and methotrexate—for treating giant cell arteritis, a serious inflammatory condition. Researchers wanted to see which medication better protected patients from major heart problems like heart attacks, strokes, and death. They analyzed data from over 1,600 patients to understand which treatment strategy might offer better long-term heart safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
APHP_ Hôpital Pitié-Salpêtrière
Paris, 75013, France
-
APHP_ Hôpital Saint-Antoine
Paris, 75012, France
Conditions
Explore the condition pages connected to this study.